Krystal Biotech has been granted a patent for a pharmaceutical composition that includes a replication defective herpes simplex virus type 1 (HSV-1) containing a recombinant HSV-1 genome encoding a transglutaminase (TGM) polypeptide. The composition also includes a pharmaceutically acceptable excipient. This patent aims to provide methods and compositions for the treatment of diseases using this recombinant nucleic acid technology. GlobalData’s report on Krystal Biotech gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Krystal Biotech, Oncolytic viruses was a key innovation area identified from patents. Krystal Biotech's grant share as of September 2023 was 25%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is granted for a pharmaceutical composition containing a recombinant herpes simplex virus type 1 (hsv-1) and a transglutaminase (tgm) polypeptide
A recently granted patent (Publication Number: US11717547B2) discloses a pharmaceutical composition comprising a replication defective herpes simplex virus type 1 (HSV-1) with a recombinant HSV-1 genome. The recombinant genome contains one or more polynucleotides encoding a transglutaminase (TGM) polypeptide. The composition also includes a pharmaceutically acceptable excipient.
The TGM polypeptide in the composition can be selected from various options, including TGM1, TGM2, TGM3, TGM4, TGM5, TGM6, and TGM7 polypeptides. Alternatively, the TGM polypeptide can be a human TGM polypeptide.
The pharmaceutical composition is suitable for administration through various routes such as topical, transdermal, subcutaneous, intradermal, or transmucosal administration. However, it is specifically mentioned that the composition is suitable for topical administration.
In addition to the TGM polypeptide, the recombinant HSV-1 genome may also contain one or more polynucleotides encoding a glycoprotein H (gH) polypeptide. The gH polypeptide can be a wild-type gH polypeptide.
The recombinant HSV-1 genome further includes an inactivating mutation in an essential immediate early gene. This essential immediate early gene can be one or both copies of an infected Cell Protein (ICP) 4 gene or an ICP27 gene.
The patent also describes a method of delivering the polynucleotides encoding a transglutaminase polypeptide into cells of a subject. This method involves administering the pharmaceutical composition, as described above, to the subject. The subject can be a human. The composition can be administered topically, transdermally, subcutaneously, intradermally, or transmucosally. However, the method specifically mentions topical administration.
Similar to the pharmaceutical composition, the method also involves the use of a recombinant HSV-1 genome containing one or more polynucleotides encoding a gH polypeptide and an inactivating mutation in an essential immediate early gene. The gH polypeptide can be a wild-type gH polypeptide, and the essential immediate early gene can be one or both copies of an ICP4 gene or an ICP27 gene.
In summary, the granted patent discloses a pharmaceutical composition and a method for delivering transglutaminase polypeptides using a replication defective herpes simplex virus type 1 (HSV-1) with a recombinant HSV-1 genome. The composition and method have potential applications in topical administration for various therapeutic purposes.
To know more about GlobalData’s detailed insights on Krystal Biotech, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
